2024 - Cannabinoid Analysis: Challenges Caused by the Proliferation of THC Isomers and Analogues

The passage of the 2018 Farm Bill, or Agricultural Improvement Act of 2018, allowed for the removal of hemp from the Drug Enforcement Administration’s (DEA) list of controlled substances. Since the passage of the Farm Bill, the hemp market has become saturated. The 2023 National Hemp Report from the National Agricultural Statistics Service (NASS) reported over 30 million pounds of hemp produced in 2022, down from 39 million pounds produced in 2021.
Unrestrained hemp production has led to an excess of hemp’s most abundant phytocannabinoid, cannabidiol (CBD). The CBD market has largely targeted health-conscious individuals in search of alternatives to pharmaceuticals. CBD is promoted in the health and fitness industry to enhance muscle recovery, reduce inflammation and pain and decrease cortisol levels.
Read more...
Moreover, the speaker will discuss the prevalent mislabeling practices in commercially available THC analogue products, often leading to the presence of additional, unreported analogues, emphasizing the need for stringent regulatory oversight and consumer awareness.
Register for this webinar today to gain insights into the challenges of cannabinoid analysis owing to the proliferation of THC analogues and the use of advanced methodologies for accurate analysis.
Keywords: Cannabis, Cannabinoids, Analytical Testing, Laboratory Technology, Hemp, CBD, Cannabidiol, Toxicology/Safety, Other Research